neutral
4 days agoLaw Firms Steer Sudeep Pharma’s Strong ₹895 Cr IPO Debut
Sudeep Pharma’s ₹895 crore IPO saw robust demand across investor categories, with overall subscription reaching 93.71 times and QIB interest hitting an impressive 213.08 times. The issue included a fresh offering and an offer for sale, guided by CAM for the company and S&R Associates along with Hogan Lovells for the book-running lead managers. The stock listed at a premium on both NSE and BSE, opening at ₹730 and ₹725 respectively.
Nseindia• By Pooja Kumari
Explore:Mutual Fund Tools
neutral
4 days agoLaw Firms Steer Sudeep Pharma’s Strong ₹895 Cr IPO Debut
Sudeep Pharma’s ₹895 crore IPO saw robust demand across investor categories, with overall subscription reaching 93.71 times and QIB interest hitting an impressive 213.08 times. The issue included a fresh offering and an offer for sale, guided by CAM for the company and S&R Associates along with Hogan Lovells for the book-running lead managers. The stock listed at a premium on both NSE and BSE, opening at ₹730 and ₹725 respectively.
Nseindia• By Pooja Kumari
Explore:Mutual Fund Tools
Recently
1 min read
72 words
Sudeep Pharma’s ₹895 crore IPO saw strong demand, listing at a solid premium with leading law firms advising across the transaction’s key components.
Sudeep Pharma’s ₹895 crore IPO saw robust demand across investor categories, with overall subscription reaching 93.71 times and QIB interest hitting an impressive 213.08 times. The issue included a fresh offering and an offer for sale, guided by CAM for the company and S&R Associates along with Hogan Lovells for the book-running lead managers. The stock listed at a premium on both NSE and BSE, opening at ₹730 and ₹725 respectively.
Sudeep Pharma’s ₹895 crore IPO saw robust demand across investor categories, with overall subscription reaching 93.71 times and QIB interest hitting an impressive 213.08 times. The issue included a fresh offering and an offer for sale, guided by CAM for the company and S&R Associates along with Hogan Lovells for the book-running lead managers. The stock listed at a premium on both NSE and BSE, opening at ₹730 and ₹725 respectively.
Nov 29, 2025 • 04:10